Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose 3.6 ...
Eli Lilly also raised its annual profit forecast by $1.30 per share to a range of $13.50 to $14 per share. The company reported an adjusted profit of $2.58 per share, topping analysts' expectations by ...
Merck, Eli Lilly, AbbVie, Bristol-Myers Squibb, Genentech, Sun Pharmaceutical, BioMimetix, Cipla, Sigma-Aldrich, Panacea Biotec, Zydus Cadila 市場レポートは、悪性神経膠腫の治療薬市場を支配するトッププレーヤーを分析します。 この調査では、悪性神経膠腫の治療薬 ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...
イーライリリー・アンド・カンパニー 企業情報 イーライ・リリー・アンド・カンパニー(Eli Lilly and Co)は、医薬品製造事業を行う。【事業内容】ヒト用医薬品セグメントにおいて、製品の創薬、開発、製造、販売を行う。糖尿病製品には、「Basaglar ...
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...